There was no apparent differences in new onset AF in a trial of patients with HFrEF randomized to vericiguat, and data is insufficient regarding effects on AF risk with hydralazine/isosorbide dinitrate, omecamtiv mecarbil, or glucagon-like peptide-1 receptor agonists. The gene discussed is GLP1R; the disease is atrial fibrillation.